ReviewAnnual review of medicine2012
New paradigms for HIV/AIDS vaccine development.
Review in Annual review of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed.
- Trial
- Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).The Journal of infectious diseases · 2013Trial
- HIV-1 Nef sequence and functional compartmentalization in the gut is not due to differential cytotoxic T lymphocyte selective pressure.PloS one · 2013Trial
- HIV-1 protease cleavage sites detection with a quantum convolutional neural network algorithm.Scientific reports · 2026Article
- Dissecting the steps in early simian immunodeficiency virus dissemination following mucosal and intravenous infection of rhesus macaques.Journal of virology · 2026Article
- Targeting MHC-E as a new strategy for vaccines and immunotherapeutics.Nature reviews. Immunology · 2026Review
- Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine.Vaccines · 2025Review
- Rapid systemic spread and minimal immune responses following SIVsab intrarectal transmission in African green monkeys.JCI insight · 2024Article
- Human cytomegalovirus UL18 prevents priming of MHC-E- and MHC-II-restricted CD8Science immunology · 2024Article
- mRNA-based HIV-1 vaccines.Clinical microbiology reviews · 2024Review
- CD8Science advances · 2024Article
- Functional genomic analysis of the 68-1 RhCMV-Frontiers in immunology · 2024Article
- Recent advances in CD8Heliyon · 2023Review
- Programming cytomegalovirus as an HIV vaccine.Trends in immunology · 2023Review
- Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.Nature reviews. Immunology · 2023Review
- Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803.Journal of virology · 2022Article
- Systemic and Intestinal Viral Reservoirs in CD4+ T Cell Subsets in Primary SIV Infection.Viruses · 2021Article
- Long-term protective immunity induced by an adjuvant-containing live-attenuated AIDS virus.NPJ vaccines · 2021Article
- A recombinant measles virus vaccine strongly reduces SHIV viremia and virus reservoir establishment in macaques.NPJ vaccines · 2021Article
- Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.PLoS pathogens · 2021Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
HIV-1 and its simian counterpart SIV have been exquisitely tailored by evolution to evade host immunity. By virtue of specific adaptations that thwart individual innate or adaptive immune mechanisms, and an overall replication strategy that provides for rapid establishment of a large, systemic viral population, capable of dynamic adaptation to almost all immune selection pressures, these viruses, once established, almost invariably stay one step ahead of the host's immune system, and in the vast majority of infected individuals, replicate indefinitely. Although many vaccine approaches tested to date have been able to enhance the magnitude of the immune responses to HIV/SIV infection, most of these responses, whether cellular or humoral, have largely failed to be both effectively antiviral and targeted to prevent the emergence of fully functional escape variants. Recent advances, however, have provided strong evidence that the initial stages of infection following mucosal transmission of these viruses are more vulnerable to immune intervention, and have led to the development of vaccine strategies that elicit responses able to effectively intervene in these early stages of infection, either preventing acquisition of infection or establishing early, stringent, and durable control. Here, we place HIV/AIDS vaccine development in the context of the basic immunobiology of HIV and SIV, review the evidence for their vulnerability to immune responses immediately after mucosal transmission, and discuss how this newly recognized vulnerability might be exploited for the development of an effective HIV/AIDS vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.